Every 10-Q that Scilex Holding Company (SCLX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SCLX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SCLX filings page.
Scilex Holding Company reported continued operating and financial pressure for the quarter and six months ended June 30, 2026. Net revenue was $7.6 million for the quarter and $16.3 million year‑to‑date, while operating expenses of $37.1 million for the quarter and $77.8 million for six months drove a loss from operations of $61.6 million year‑to‑date.
Total other expense of $99.0 million for the six months was dominated by unrealized and realized losses on the Datavault equity method investment, losses on digital assets, and fair‑value changes in debt and derivative instruments, resulting in a six‑month net loss attributable to common stockholders of $158.0 million. The balance sheet shows $253.6 million in total assets against $564.1 million in total liabilities and a stockholders’ deficit of $310.5 million, including an accumulated deficit of $1.08 billion. Cash and cash equivalents were only $0.6 million and working capital was negative by about $476 million, leading management to state that substantial doubt exists about Scilex’s ability to continue as a going concern absent additional financing and improved product sales.
Scilex Holding Company reported a larger quarterly loss while remaining in a significant deficit position. For the three months ended March 31, 2026, net revenue was $8.6M, up from $5.0M a year earlier, but operating expenses of $40.8M drove a loss from operations of $32.2M.
After sizable fair value movements on derivatives, digital assets and equity investments, Scilex recorded a net loss attributable to common stockholders of $43.3M versus $26.1M in 2025. Cash and cash equivalents were $3.4M, with total assets of $293.6M and total liabilities of $547.7M, resulting in stockholders’ deficit of $249.2M. Management disclosed negative working capital of $459.8M and substantial doubt about the company’s ability to continue as a going concern, noting dependence on future financings and growth in sales of ZTlido, ELYXYB and GLOPERBA. The quarter also reflected a $65.3M balance of digital assets (Bitcoin) and an equity-method Datavault investment of $79.1M, with large unrealized and realized valuation swings affecting results.
Scilex Holding Company (SCLX) filed its Q3 2025 report, highlighting steep losses and liquidity strain. Net revenue was $10.6 million, down from $14.4 million a year ago, while selling, general and administrative expenses surged to $188.8 million. Loss from operations reached $186.5 million, and net loss was $257.8 million for the quarter.
The balance sheet shows cash and cash equivalents of $0.9 million against total liabilities of $455.6 million and a stockholders’ deficit of $176.9 million. Accrued rebates and fees were $213.4 million, and derivative liabilities rose to $82.0 million. The company adopted a cryptocurrency treasury strategy; digital assets were recorded at $196.6 million, including Bitcoin acquired via equity consideration. Management stated conditions that raise substantial doubt about the company’s ability to continue as a going concern.
Operationally, Scilex initiated a second Phase 3 study for SP-102 in September 2025 and noted Health Canada’s approval of ELYXYB earlier in the year. A 1‑for‑35 reverse stock split was effected in April 2025, with a $43.8 million deemed dividend tied to certain warrants.